![]() |
|
|
Vol. 289, Issue 1, 211-218, April 1999
Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, California
| |
Abstract |
|---|
|
|
|---|
A time course study was carried out to elucidate the mechanisms for antifibrotic effect of pirfenidone (PD). Hamsters were intratracheally (i.t.) instilled with saline (SA) or bleomycin (BL) (7.5 units/kg/5 ml). The animals were fed a diet containing 0.5% PD or the same control diet (CD) without the drug 2 days before and throughout the study. The animals were sacrificed at various times after instillation. The lung hydroxyproline level in BL + CD groups was gradually increased and peaked at 21 days to 181% of the SA + CD control. The BL + PD-treated groups showed a gradual decrease in their lung collagen content, showing a maximum reduction of 40% at day 21. The lung malondialdehyde levels of the BL + CD groups were increased by several-fold of the corresponding SA + CD groups at various times. The lung prolyl hydroxylase (PH) activities in the BL + CD groups were also increased by several-fold of the corresponding SA + CD groups at these time points. The hamsters in the BL + PD showed a gradual decrease in the lung malondialdehyde levels from 10 to 21days compared with their corresponding BL + CD groups. Treatment with PD also reduced the lung PH activities in the BL + PD groups compared with the corresponding BL + CD groups. However, PD failed to manifest any direct inhibitory effect on PH activity in vitro. BL treatment increased the lung procollagen I and III gene expressions in the BL + CD groups by several-fold at varying times compared with the corresponding SA + CD, and treatment with PD in the BL + PD groups significantly down-regulated the BL-induced overexpression of these genes. Studies evaluating the regulation of these genes at the transcriptional level revealed PD significantly reduced the transcription of PC I at 14 days. Our results indicate that the antifibrotic effect of PD was partly due to suppression of the BL-induced inflammatory events and partly due to down-regulation of BL-induced overexpression of lung procollagen I and III genes.
| |
Introduction |
|---|
|
|
|---|
Interstitial
pulmonary fibrosis (IPF) continues to remain a challenging and
perplexing problem for both researchers and clinicians. IPF is a
crippling disease with a survival rate of less than 5 years. There is
no known effective therapy for treating this disease. The current and
most common therapy involves treatment with corticosteroids. However,
fewer than 20% of the patients respond to this line of therapy.
Moreover, corticosteroid therapy is associated with severe side effects
(Hunninghake and Kalica, 1996
).
IPF is the result of a wide variety of injuries to the lung (DePaso and
Winterbauer, 1991
). The development of fibrosis initially involves all
aspects of inflammation, including microcirculatory changes, production
of lipid-derived different mediators and cytokines, infiltration of
immune cells, and cell-cell interaction and fibroblast proliferation
followed by scarring (Sheppard and Harrison, 1992
). The hallmark of
lung fibrosis is an increase in extracellular matrix production in
response to proliferating lung fibroblasts, and this results in an
excess deposition of collagen in the lung interstitium (Crouch, 1990
).
In the bleomycin (BL) rodent model of lung fibrosis, the increase in
collagen production has been attributed to both the increase in the
number of fibroblasts and the increase in the amount of collagen
synthesized by each fibroblast (Goldstein and Fine, 1986
). The amount
of collagen deposited in the lung is controlled by a balance between
synthesis, regulated transcriptionally, translationally, and
post-translationally, and degradation, regulated by a whole host of
enzymes and their inhibitors (McAnulty and Laurent, 1995
). The balance
between collagen synthesis and degradation can be tipped off in favor
of synthesis by numerous factors like increases in fibrogenic cytokines
and growth factor productions. This would then result in an excess
buildup of collagen in the lung interstitum. In fact, accumulation of
collagen in response to increased synthesis has been demonstrated in
experimental models of lung fibrosis in hamsters and rabbits and a
decreased degradation in rabbits as well (Seyer et al., 1976
; Clark et
al., 1983
; Laurent et al., 1983
). An excess accumulation of collagen
has also been reported in humans with idiopathic pulmonary fibrosis
(Seyer et al., 1976
). The molecular basis of increased collagen
synthesis during the course of the development of lung fibrosis appears
to be an overexpression of procollagen (PC) I and III and transforming
growth factor-
(TGF-
) and fibronectin genes (Raghow et al.,
1985
), and this involves both transcriptional and post-transcriptional
mechanisms (Raghow et al., 1985
, 1987
; Breen et al., 1992
).
Several animal models are used to investigate the molecular mechanisms
of pulmonary fibrosis. The most widely used model is the intratracheal
(i.t.) instillation of BL in the rodents. This model produces
histological lesions and biochemical changes that resemble IPF seen in
humans (Giri et al., 1980
). The BL rodent model is used for studying
the pathogenesis of lung fibrosis (Thrall et al., 1979
) and for rapid
screening of drugs for their potential antifibrotic effects (Zuckerman
et al., 1980
; Iyer et al., 1995
).
Our laboratory has demonstrated the antifibrotic effects of pirfenidone
(PD) in the BL hamster model of lung fibrosis (Iyer et al., 1995
). PD
was also found to retard the progression of an on-going fibrotic
process in the same model (Iyer et al., 1998a
). However, the molecular
mechanisms for the antifibrotic effect of this novel compound are not
known. This study was designed as part of a long-term goal of exploring
the possible mechanisms for the antifibrotic effect of PD in the BL
hamster model of lung fibrosis.
We hypothesized that the reduction in collagen content due to PD treatment could be due to initially by suppression of BL-induced lung inflammation followed by a down-regulation of BL-induced overexpression of PC I and III genes. The present study was designed to test this hypothesis by studying the effects of dietary intake of PD on BL-induced increases in lung lipid peroxidation (index of inflammation), prolyl hydroylase (PH) activity (enzyme responsible for post-translational modification of collagen), hydroxyproline content (index of collagen) and PC I and III mRNA accumulation. To determine whether transcriptional and/or posttranscriptional processes are involved, we also investigated whether the alteration in PC I and III gene expression by PD occurred at the level of gene transcription after BL instillation at 14 days and whether PD had any direct effect on PH activity in an in vitro study.
| |
Materials and Methods |
|---|
|
|
|---|
Treatment of Animals.
Male golden Syrian hamsters weighing
90 to 110 g were purchased from Simonsens, Inc. (Gilroy, CA).
Hamsters were housed in groups of four in facilities with filtered air
and constant temperature and humidity. All care was in accordance with
the National Institutes of Health guidelines for animal welfare. The
hamsters were acclimatized for 1 week before any treatment. A 12/12-h
light/dark cycle was maintained, and the animals had access to water
and either pulverized Rodent Laboratory Chow 5001 (Purina Mills, Inc.,
St. Louis, MO) or the same pulverized chow containing PD (0.5% w/w).
PD was generously supplied by Dr. Margolin (Marnac, Inc., Dallas, TX).
The hamsters were fed these diets 2 days before i.t. instillation and
throughout the study period. Hamsters were instilled i.t. with saline
(SA) or BL (7.5 units/kg/5 ml). The animals were randomly divided into four experimental groups: 1) SA-instilled animals fed the control diet
(CD) (SA + CD), 2) SA-instilled animals fed PD in the same diet (SA + PD), 3) BL-instilled animals fed the CD (BL + CD), and 4) BL-instilled
animals fed PD in the same diet (BL + PD). The animals were sacrificed
at 3, 7, 10, 14, and 21 days after the BL or SA instillation by
decapitation, and their lungs were removed and freeze-clamped, dropped
in liquid nitrogen, and stored at
80°C until used for mRNA
analysis. The major portion of the sample was used for direct total RNA
isolation, and the remainder was used for other biochemical studies.
Tissue Processing for Biochemical Study.
The frozen lungs
were thawed and homogenized in 0.1 M KCl/0.02 M Tris·HCl buffer, pH
7.6, with a Polytron homogenizer (Brinkmann Instruments Inc.,
Weastbury, NY). After recording the total homogenate volume (5-6 ml),
it was mixed, divided into aliquots, and stored at
80°C, except for
the aliquots for lipid peroxidation and hydroxyproline assays, which
were processed and assayed the same day on which the lungs were homogenized.
Determination of Lipid Peroxidation.
The lung
malondialdehyde equivalent (MDAE) level, an index of lipid
peroxidation, was determined in the whole homogenate according to the
method of Ohkawa et al. (1979)
.
Determination of PH Activity.
The method for PH assay was
the same as reported previously and is based on the release of
tritiated water from 3,4-[3H]proline-labeled
unhydroxylated PC substrate prepared in vitro using 10-day-old
embryonic chick tibiae (Giri et al., 1983
). During the reaction,
tritium is released in stoichiometric proportion to prolyl
hydroxylation as tritiated water, which is collected and counted as a
measure of the PH activity (Hutton et al., 1966
). The activity was
expressed as the total dpm released/lung/30 min.
Determination of PH Activity In Vitro.
Five control hamsters
not subjected to any treatment were first anesthetized with sodium
pentobarbital (80-100 mg/kg). Their lungs were perfused with ice-cold
isotonic SA; then, all lung lobes were dissected out and rinsed in SA.
They were immediately homogenized in buffer containing 0.1 M Tris and
0.05% Triton X. The homogenate was spun down at 6000g for
20 min at 4°C. The supernatant was gently aspirated and used to
determine PH activity and its protein content. The procedure to measure
the PH activity was essentially the same as described above. Briefly,
the reaction mixture in a total volume of 2.2 ml consisted of 200 µl
of
-ketoglutarate (0.001 M), 200 µl of ferrous ammonium sulfate
(0.005 M), 250 µl of supernatant as enzyme source, 200 µl of PD to
produce the desired final concentration, 200 µl of Tris·HCl (1 M),
and 20 µl of 3H-unhydroxylated PC substrate
(400,000 cpm). The reaction mixture was first preincubated with PD at
different concentrations for 30 min at 37°C in a shaking water bath.
The reaction was started by adding 200 µl of ascorbic acid (0.005 M);
30 min later, the reaction was terminated by adding 200 µl of 50%
trichloroacetic acid. The tritiated water released was collected by
vacuum distillation. Then 1 ml of the tritiated water was mixed with 10 ml of Ready Safe liquid scintillation cocktail (Beckman), and the
radioactivity was determined at 45% counting efficiency in a
scintillation counter. Protein content of the supernatant was
determined according to the method of Lowry et al. (1951)
. The PH
activity was expressed as total dpm associated with tritiated water
released in the reaction mixture/mg protein/30 min.
Determination of Hydroxyproline.
For assay of lung
hydroxyproline as a measure of collagen content, 1 ml of whole
homogenate was precipitated with 0.25 ml of ice-cold 50% (w/v)
trichloroacetic acid and centrifuged, and the precipitate was
hydrolyzed in 2 ml of 6 N HCl for 18 h at 110°C. The
hydroxyproline content was measured according to the method of Woessner
(1961)
.
Total RNA Isolation and Hybridization Analysis.
Total RNA
isolation from hamster whole lung samples were carried out according to
the method of Chomczynski and Sacchi (1987)
. The Northern blot
experiments were performed as described previously by the method of
Gurujeyalakshmi et al. (1996)
. Total RNA (10 µg/lane) was
electrophoresed through 1% agarose/2.2 M formaldehyde gels and
transferred to a nylon membrane. The membranes were UV cross-linked (UV
Stratalinker; Stratagene, La Jolla, CA). One set of the membranes were
stained with methylene blue to confirm uniformity of RNA loading,
transfer, and integrity. Prehybridization was carried out on another
set of membranes at 42°C for 2 to 3 h in a solution containing
50% formamide, 5× sodium chloride sodium phosphate EDTA, 0.5% SDS,
and 200 µg/ml sheared salmon sperm DNA. For hybridization, the
radiolabeled probes were prepared by the random primer method (Bio-Rad,
Richmond, CA). The denatured, 32P-labeled cDNA
probes of either PC I, PC III, or 18S rRNA were added to the
prehybridization buffer, and hybridization was carried out at 42°C
for 16 for 20 h. After hybridization, the membranes were washed as
described previously (Gurujeyalakshmi et al., 1996
) and exposed to Fuji
X-ray film at
80°C with intensifying screens. The intensity of each
band was determined by using the dual-wavelength flying spot scanning
densitometer (model CS-9301PC; Shimadzu, Columbia, MD). The band
intensity for PC I or PC III was divided by the band intensity of 18S
rRNA to correct for variations in the quantity of RNA loaded. The ratio
of the signal intensities of PC I mRNA/18S mRNA and PC III mRNA/18S
mRNA are expressed as arbitrary units.
Nuclear Run-Off Transcription Analysis.
The isolation of
nuclei from the whole hamster lungs and the in vitro transcriptional
reactions involving the labeling of the nascent RNA were performed
according to the method of Gurujeyalakshmi et al. (1996)
. A slot-blot
apparatus was used to prepare nytran membranes containing 20 µg/slot
of plasmid DNA with cDNA inserts encoding PC I, PC III, and 18S rRNA.
Then 20 µg of insert-free pBR322 vector was also included as a
control for nonspecific binding. The plasmids were linearized,
denatured, and neutralized before being blotted onto the membranes. The
membranes were air dried for 20 min and UV cross-linked (UV
Stratalinker; Stratagene). Then, they were prehybridized in 6× sodium
chloride sodium phosphate EDTA, 0.5% SDS, and 200 µg/ml sheared
salmon sperm DNA for 2 to 3 h at 65°C and hybridized for 36 to
40 h at 65°C with 32P-labeled nascent RNAs
(2-4 × 106 cpm) per assay and washed in
solutions of increasing stringency. The membrane strips were exposed to
Fuji X-ray film for 48 to 72 h at
80°C with intensifying
screens. The intensity of the DNA-RNA binding was determined by using
the dual-wavelength flying spot scanning densitometer (model CS-9301PC;
Shimadzu, Columbia, MD).
Molecular Probes.
The collagen and 18S rRNA probes were
obtained from American Type Culture Collection (Rockville, MD). They
included the clone HF677, containing the cDNA insert coding for PC I
(
1), a 1.8-kb EcoRI fragment; clone
HF934 containing the cDNA insert coding for PC III
(
1), a 1.3-kb
EcoRI/HindIII fragment and 18S ribosomal RNA
clone PN29III with a 0.752-kb BamHI and SphI cDNA
insert. The plasmid pBR322 was purchased from Pharmacia (Piscataway,
NJ). The plasmids were isolated using standard procedures; after
endonuclease restriction digestion, the inserts were purified with a
Qiagen gel extraction kit (Qiagen, Chatsworth, CA).
Statistical Analysis.
All data are expressed as mean ± S.E.M. BL treatment increases the amount of proteins of extrapulmonary
origin that can result in the artificial lowering of all values
(Karlinski and Goldstein, 1980
). Thus, the in vivo data are expressed
on the basis of per lung. The data were compared within the four groups
at the corresponding times using the two-way ANOVA where four groups
were involved and the t test between the two groups. A value
of P
.05 was considered to be the minimum level of
statistical significance.
| |
Results |
|---|
|
|
|---|
Lung Malondialdehyde Level.
The levels of lung MDAE for
various treatment groups are shown in Fig.
1. The MDAE values for both SA-treated
control groups SA + CD and SA + PD averaged 60 ± 5 and 65 ± 4 nmol/lung, respectively. The i.t. instillation of BL significantly
increased the MDAE values to 226%, 376%, and 202% of the
corresponding SA + CD control groups at 10, 14, and 21 days,
respectively. Treatment with PD significantly reduced these values to
81%, 123%, and 111% of their respective BL + CD groups at the
corresponding times.
|
PH Activity.
The PH activity in various groups is shown in
Fig. 2. There was no significant
difference in the PH activity between the two SA-treated SA + CD and SA + PD control groups at 3, 7, 10, 14, and 21 days. Treatment with BL
increased the PH activity from 7 through 21 days in the BL + CD groups.
Significant increases in PH activity occurred in these groups at 7, 10, 14, and 21 days by 208%, 359%, 240%, and 148% of their
corresponding SA + CD control groups, respectively. Treatment with PD
significantly reduced the PH activity in the BL + PD groups by 110%,
170%, and 85% at 10, 14, and 21 days compared with their
corresponding BL + CD groups, respectively.
|
Lung PH Activity In Vitro. The direct effect of different concentrations of PD on the PH activity in vitro is shown in Table 1. The PH activity remained unchanged at any concentrations of PD because the activity was more or less the same in all cases with or without the PD preincubation of the enzyme .
|
Lung Hydroxyproline Level.
The effects of i.t. instillation of
BL with and without PD treatment on the lung hydroxyproline levels at
various times are summarized in Fig. 3.
There were no significant differences in the lung hydroxyproline levels
among the four groups at 3, 7, and 10 days after i.t. instillation of
BL. However, the lung hydroxyproline levels in the BL-treated hamsters
in the BL + CD groups were significantly increased to 1405 ± 37 and 1553 ± 14 µg/lung at 14 and 21 days compared with their
corresponding SA + CD control groups, respectively. Treatment with PD
caused significant reductions in the hydroxyproline levels to 1001 ± 114 and 941 ± 42 µg/lung in the BL + PD groups at 14 and 21 days compared with the corresponding BL + CD groups, respectively.
|
PC I Gene Expression.
The kinetics of PC I gene expression are
shown in Fig. 4. The Northern blot
analysis was carried out to determine the effect of PD in
down-regulating the BL-induced overexpression of PC I mRNA. Treatment
with BL gradually increased the PC I gene expression in the BL + CD
groups from 7 to 21 days, peaking at 10 days. There was a significant
increase in the PC I gene expression at 10, 14, and 21 days by 777%,
475%, and 462% of the corresponding SA + CD control groups,
respectively. Treatment with PD gradually reduced the PC I gene
expression in the BL + PD groups and showed significant reductions at
10, 14, and 21 days by 71%, 62%, and 77% compared with the
corresponding BL + CD groups, respectively. Figure
5 represents the Northern blot and
densitometric reading showing the overexpression of PC I gene in the BL + CD group and its down-regulation in the BL + PD group.
|
|
PC III Gene Expression.
The kinetics of PC III gene expression
with and without PD treatment are shown in Fig.
6. Treatment with BL in BL + CD groups significantly increased the PC III gene expression at 14 and 21 days to
278% and 428% of their corresponding SA + CD groups. Dietary intake
of PD significantly reduced the PC III gene expression in BL + PD
groups by 76% and 85% of the corresponding BL + CD group at 14 and 21 days, respectively. Figure 7 represents
the Northern blot and densitometric reading showing the overexpression of PC III gene in BL + CD groups and its down-regulation in BL + PD
group.
|
|
Regulation of PC Genes at Transcriptional Level.
We carried
out a nuclear run-off transcription assay to determine whether the
inhibition of PC I and III gene expression by PD is mediated by an
alteration in gene transcription. Newly synthesized RNA transcripts
from lung nuclei of hamsters in SA + CD, SA + PD, BL + CD, and BL + PD
groups were isolated at 14 days after i.t. instillation of SA or BL as
described in Materials and Methods. The transcription of PC
I and III mRNAs was easily detectable in the nuclei prepared from lungs
of hamsters in BL + CD and BL + PD groups. In contrast, we were not
able to detect any transcripts of PC I or PC III in nuclei prepared
from the lungs of hamsters in SA + CD and SA + PD groups. As shown in
Fig. 8 and Table 2, the
labeled transcripts that hybridized to cDNA of PC I were reduced significantly by 50% in the BL + PD group compared with the BL + CD
group at 14 days. Although the transcription of PC III gene in the BL + PD group was less than that of BL + CD group, it was not significantly
different. There was no difference at 14 days in the transcription of
the gene encoding for 18S rRNA in the lung nuclei of hamster between
the BL + CD and BL + PD groups. These results demonstrate that PD
treatment down-regulates the BL-induced overexpression of PC I mRNA
specifically at the transcriptional level.
|
|
| |
Discussion |
|---|
|
|
|---|
BL-induced lung injury involves damage to the epithelial and
endothelial cells of the lung, followed by infiltration of the inflammatory cells. These cells include predominantly neutrophils and
macrophages, with some lymphocytes and eosinophils (Giri et al., 1986
).
The inflammatory process is highly amplified by the production of
reactive oxygen species (ROS). In the BL model of lung injury,
neutrophils are known to be sequestered very early into the lung,
generating various proteolytic enzymes and free radicals. The
neutrophils contain myeloperoxidase which catalyzes a reaction of
H2O2 with
Cl
to form HOCl, which is reactive, cytotoxic,
and injurious to the parenchymal cells (Klebenoff, 1988
). The
macrophages also generate ROS during phagocytosis, but more
importantly, they release various proinflammatory cytokines and growth
factors that cause fibroblast proliferation at the sites of the injury
(Rennard et al., 1981
; Kelly, 1990
). In addition, BL binds to DNA and
Fe2+, undergoes redox cycling, and generates ROS
like superoxide and hydroxy radicals (Suguira et al., 1978; Caspary et
al., 1982
). These radicals are known to cause DNA strand scission and
lipid peroxidation, resulting in damage to the lung (Giri et al.,
1983
). We found significant increases in the lung lipid peroxidation as
reflected by the MDAE content in the BL + CD groups from day 10 through
day 21, and treatment with PD significantly reduced the lung lipid
peroxidation content at these time points. We previously demonstrated
that dietary intake of PD decreased the BL-induced increases in the
lung superoxide dismutase activity (Iyer et al., 1995
, 1998a
),
indicating a lower level of ROS formation in the BL + PD than in the BL + CD groups. Furthermore, PD was found to be an effective scavenger of
O2
,
OH
, and
H2O2 generated in vitro
(Valeyathan et al., 1996
). Thus, it is possible that the antifibrotic
action of PD may partly reside in its ability to scavenge the ROS
generated by inflammatory cells and/or by the redox cycling of
BL/DNA/Fe2+ complex. Thus it is highly likely
that a reduction in the extent of ROS-induced lung damage by PD
treatment in BL + PD group may subsequently attenuate the ensuing
cascade of events which generally lead to the development of lung fibrosis.
Fibrosis is generally a final outcome of the inflammatory process. One
of the strategies against the development of lung fibrosis is to
down-regulate the excess collagen production. The synthesis of collagen
involves transcription of the PC mRNA in the nucleus, which is
translocated to the endoplasmic reticulum to translate PC polypeptide
chains (McAnulty and Laurent, 1995
). We observed a marked up-regulation
in the PC I and PC III mRNA levels in the lungs of hamsters in BL + CD
groups beginning from day 10 through day 21. This overproduction in the
PC mRNAs in response to BL treatment is attributed to an increase in
the rate of mRNA transcription and a prolonged half-life of the mRNAs
(Raghow et al., 1985
, 1987
). The observed down-regulation of the mRNAs
levels by PD treatment in the BL + PD group from day 10 through day 21 could be due to a reduction in the transcription rate and the message
stability resulting from increased degradation or other factors that
could affect the transcription or mRNA accumulation. Our study
demonstrates that treatment with PD down-regulated the PC I gene
transcription by 50% in the BL + PD group compared with the BL + CD
group at 14 days but had little effect on PC III gene transcription.
Our results also indicate that treatment with PD did not alter the rate
of PC III gene transcription. The reasons for this differential effects
of PD on gene transcription of PCs I and III are not clear; however, it
is possible that the transcriptional down-regulation of PC III by PD
might have occurred earlier than 14 days. In any event, the present
study suggests that the observed reduction in PC I gene expression by
PD treatment is regulated at least in part at the transcriptional level.
The increase in collagen synthesis is also regulated by various
cytokines and growth factors (Kelly et al., 1990
). In this regard,
TGF-
is of particular interest because it is well known to be
involved in the pathogenesis of lung fibrosis (Khalil et al., 1991
),
and it probably functions as a master switch in triggering the
sequentially interconnected events that lead to an excess deposition of
collagen for the following reason. It has been demonstrated that
increased TGF-
mRNA transcription is followed by TGF-
mRNA accumulation and TGF-
protein, which precedes PC gene transcription followed by increased collagen synthesis and deposition (Breen et al.,
1992
; King et al., 1994
). The data presented in the present report
suggest that PD exerts its effect in part proximally at the
transcriptional level and down-regulates the BL-induced overexpression of PC mRNAs by down-regulating the BL-induced overexpression of TGF-
mRNA and TGF-
protein, as shown in our preliminary study (Iyer et
al., 1997
, 1998b
).
After the translocation of the PC mRNA to the endoplasmic reticulum to
form polypeptide chain, it undergoes a number of cotranslational and
post-translational modifications: initially, the hydroxylation of the
proline residues catalyzed by PH, followed by glycosylation and
secretion into extracellular space and cross-linking. The prolyl-4-hydroxylase catalyzed hydroxylation of proline is required for
both stability and secretion of tropocollagen (Kivirikko et al., 1990
).
If this enzyme is inhibited, triple helix tropocollagen formation will
not occur, and this will promote a rapid degradation of unhydroxylated
pro-
chains as demonstrated by various investigators (Philajameni et
al., 1991). The data presented here are consistent with those of the
latter study; BL treatment in the BL + CD group had significantly
higher lung PH activity, which preceded the accumulation of collagen in
the lung, and PD treatment, which inhibited the PH activity in the BL + PD group, also reduced the lung collagen accumulation in this group.
Interestingly, PD structurally resembles certain PH inhibitors like
pyridine 2,4-dicarboxylate (Dowell and Hadley, 1992
). It is possible
that PD could be acting as an inhibitor of prolyl-4-hydroxylase, thus
reducing the hydroxylation of proline residues and allowing the
deposition of a more pliable and soluble form of collagen. However, our
in vitro experiment completely ruled out that possibility and
demonstrated unequivocally that PD had no direct inhibitory effect on
PH activity. Nevertheless, it is possible that PD may be indirectly
inhibiting the activity of this enzyme in vivo by suppressing the
BL-induced increased production of various cytokines and chemokines and
lipid-derived mediators of inflammation.
From our study, it appears that the antifibrotic effect of PD could be
attributed to attenuation of the inflammatory events by both the
reduced influx of inflammatory cells into the lung and the ability of
PD to scavenge free radicals. The observed down-regulation of PC gene
expression by PD treatment in the BL + PD group can be attributed to
its direct effect at the transcription of PC I gene and/or via
fibrogenic cytokines like TGF-
. Our studies also indicate that PD is
not a direct inhibitor of prolyl-4-hydroxylase. The results of this
study strongly suggest the involvement of a transcriptional mechanism
at least in part for the decreased level of PC mRNA and collagen content.
This is the first mechanistic study that demonstrates multiple sites of action of PD in minimizing the BL-induced lung collagen accumulation. The antifibrotic effect of PD has been demonstrated in other models, including cyclophosphamide mouse model (Keher and Margolin, 1997). Although the latter study was not designed to define the mechanism, it is possible that PD might be exerting its antifibrotic effect even in that model via one of the mechanisms reported here. The data presented in this investigation once again demonstrate that PD is a novel antifibrotic agent, and if pretreatment or treatment with this compound is instituted at early phases of the development of lung fibrosis, it may offer beneficial effects against this crippling disease, which has so far defied all known therapeutic modalities.
| |
Footnotes |
|---|
Accepted for publication November 11, 1998.
Received for publication March 25, 1998.
1 This work was supported by National Heart, Lung, and Blood Institute Grant R01-HL56262.
Send reprint requests to: Dr. Shri N. Giri, Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA 95616. E-mail: sngiri{at}ucdavis.edu
| |
Abbreviations |
|---|
IPF, interstitial pulmonary fibrosis;
i.t., intratracheal;
BL, bleomycin;
PC, procollagen;
PD, pirfenidone;
SA, saline;
CD, control diet;
TGF-
, transforming growth factor-
;
MDAE, malondialdehyde equivalent;
ROS, reactive oxygen species;
PH, prolyl hydroxylase;
UV, ultraviolet.
| |
References |
|---|
|
|
|---|
and fibroblast collagen synthesis in chronic pulmonary inflammation.
Am J Respir Cell Mol Biol
6:
146-152.
gene expression by pirfenidone in the bleomycin-hamster model of lung fibrosis.
Am J Respir Crit Care Med
155:
741.
by pirfenidone in the bleomycin-model of lung fibrosis.
Fed Am Soc Exp Biol
12:
A770.
in idiopathic pulmonary fibrosis.
Am J Respir Cell Mol Biol
5:
155-162.
1 collagen promoter through intracellular and extracellular signalling.
J Biol Chem
269:
13156-13161
increases steady state levels of type I procollagen and fibronectin mRNAs post transcriptionally in cultured human dermal fibroblasts.
J Clin Invest
79:
1258-1288.This article has been cited by other articles:
![]() |
P. Rogliani, M. Mura, M. Assunta Porretta, and C. Saltini Review: New perspectives in the treatment of idiopathic pulmonary fibrosis Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 75 - 93. [Abstract] [PDF] |
||||
![]() |
T J Williams and J W Wilson Challenges in pulmonary fibrosis: 7 {middle dot} Novel therapies and lung transplantation Thorax, March 1, 2008; 63(3): 277 - 284. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. W. Lee, T. H. Everett IV, D. Rahmutula, J. M. Guerra, E. Wilson, C. Ding, and J. E. Olgin Pirfenidone Prevents the Development of a Vulnerable Substrate for Atrial Fibrillation in a Canine Model of Heart Failure Circulation, October 17, 2006; 114(16): 1703 - 1712. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. I. Chaudhary, A. Schnapp, and J. E. Park Pharmacologic Differentiation of Inflammation and Fibrosis in the Rat Bleomycin Model Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 769 - 776. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Sugaru, M. Sakai, K. Horigome, T. Tokunaga, M. Kitoh, W. E. Hume, R. Nagata, T. Nakagawa, and M. Taiji SMP-534 inhibits TGF-{beta}-induced ECM production in fibroblast cells and reduces mesangial matrix accumulation in experimental glomerulonephritis Am J Physiol Renal Physiol, November 1, 2005; 289(5): F998 - F1004. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Azuma, T. Nukiwa, E. Tsuboi, M. Suga, S. Abe, K. Nakata, Y. Taguchi, S. Nagai, H. Itoh, M. Ohi, et al. Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., May 1, 2005; 171(9): 1040 - 1047. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kakugawa, H. Mukae, T. Hayashi, H. Ishii, K. Abe, T. Fujii, H. Oku, M. Miyazaki, J. Kadota, and S. Kohno Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis Eur. Respir. J., July 1, 2004; 24(1): 57 - 65. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Gross and G. W. Hunninghake Idiopathic Pulmonary Fibrosis N. Engl. J. Med., August 16, 2001; 345(7): 517 - 525. [Full Text] [PDF] |
||||
![]() |
T. Yehualaeshet, R. O'Connor, A. Begleiter, J. E. Murphy-Ullrich, R. Silverstein, and N. Khalil A CD36 Synthetic Peptide Inhibits Bleomycin-Induced Pulmonary Inflammation and Connective Tissue Synthesis in the Rat Am. J. Respir. Cell Mol. Biol., August 1, 2000; 23(2): 204 - 212. [Abstract] [Full Text] |
||||
![]() |
S. N. Iyer, G. Gurujeyalakshmi, and S. N. Giri Effects of Pirfenidone on Transforming Growth Factor-beta Gene Expression at the Transcriptional Level in Bleomycin Hamster Model of Lung Fibrosis J. Pharmacol. Exp. Ther., October 1, 1999; 291(1): 367 - 373. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||